Mr. Chan and Dr. Kahler own stock and/or hold stock options in Novartis.
2151-4658/asset/olbannerleft.gif?v=1&s=75d1dd4933b4687fdb365bb32190b0a4ef453ee7)
2151-4658/asset/olbannerright.gif?v=1&s=a36ba6af41bd9af370864f6461a516746a709d31)
Osteoporosis
You have full text access to this OnlineOpen article
Bone density consequences of initiation and compliance with therapy for osteoporosis
Article first published online: 23 MAY 2010
DOI: 10.1002/acr.20261
Copyright © 2010 by the American College of Rheumatology
Additional Information
How to Cite
Yood, R. A., Andrade, S. E., Mazor, K. M., Fouayzi, H., Chan, W. and Kahler, K. (2010), Bone density consequences of initiation and compliance with therapy for osteoporosis. Arthritis Care Res, 62: 1440–1445. doi: 10.1002/acr.20261
- †
Mr. Chan and Dr. Kahler own stock and/or hold stock options in Novartis.
Publication History
- Issue published online: 23 MAY 2010
- Article first published online: 23 MAY 2010
- Accepted manuscript online: 23 MAY 2010 12:00AM EST
- Manuscript Accepted: 11 MAY 2010
- Manuscript Received: 7 FEB 2010
Funded by
- Novartis Pharmaceuticals Corporation
REFERENCES
- 1, , , , , , et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414–9.
- 2, , , . Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645–52.
- 3, , . Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 2008; 35: 1865–73.
- 4, , , , , , et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013–22.
- 5, , , , . Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010; 21: 145–55.
- 6, , , . Consequences of poor compliance with bisphosphonates. Bone 2007; 41: 882–7.
- 7, , , . Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008; 19: 511–7.
- 8, , , , . Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 2008; 19: 1421–9.
- 9, , , , . A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007; 23: 585–94.
- 10, , , . Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008; 23: 1569–75.
- 11, , . Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 2008; 30: 2410–22.
- 12, , . Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 2009; 24: 1819–26.
- 13, , , , , . Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008; 23: 1815–21.
- 14, , , . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
- 15, , . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–9.
- 16, , , , , , et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44–7.
- 17, , , , , . Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965–8.
- 18, , , . Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280–8.
- 19, , , , , , et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009; 44: 153–9.